HomeCompareGBIO vs EPRT

GBIO vs EPRT: Dividend Comparison 2026

GBIO yields 37.45% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBIO wins by $138.2K in total portfolio value
10 years
GBIO
GBIO
● Live price
37.45%
Share price
$5.34
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$201.6K
Annual income
$32,248.55
Full GBIO calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — GBIO vs EPRT

📍 GBIO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBIOEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBIO + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GBIO pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBIO
Annual income on $10K today (after 15% tax)
$3,183.52/yr
After 10yr DRIP, annual income (after tax)
$27,411.27/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, GBIO beats the other by $16,496.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBIO + EPRT for your $10,000?

GBIO: 50%EPRT: 50%
100% EPRT50/50100% GBIO
Portfolio after 10yr
$132.5K
Annual income
$22,544.63/yr
Blended yield
17.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

GBIO
Analyst Ratings
5
Buy
5
Hold
Consensus: Buy
Price Target
$5.25
-1.7% upside vs current
Range: $5.00 — $5.50
Altman Z
-9.1
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBIO buys
0
EPRT buys
0
No recent congressional trades found for GBIO or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBIOEPRT
Forward yield37.45%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$201.6K$63.4K
Annual income after 10y$32,248.55$12,840.73
Total dividends collected$148.7K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$5.25$35.50

Year-by-year: GBIO vs EPRT ($10,000, DRIP)

YearGBIO PortfolioGBIO Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$14,445$3,745.32$11,205$505.18+$3.2KGBIO
2$20,513$5,056.29$12,672$682.46+$7.8KGBIO
3$28,659$6,710.36$14,490$930.48+$14.2KGBIO
4$39,427$8,761.91$16,786$1,282.69+$22.6KGBIO
5$53,452$11,265.44$19,753$1,791.56+$33.7KGBIO
6$71,468$14,273.72$23,677$2,541.64+$47.8KGBIO
7$94,307$17,835.96$29,008$3,672.99+$65.3KGBIO
8$122,904$21,996.02$36,463$5,425.08+$86.4KGBIO
9$158,298$26,790.73$47,238$8,221.57+$111.1KGBIO
10$201,627$32,248.55$63,385$12,840.73+$138.2KGBIO

GBIO vs EPRT: Complete Analysis 2026

GBIOStock

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Full GBIO Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this GBIO vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBIO vs SCHDGBIO vs JEPIGBIO vs OGBIO vs KOGBIO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.